Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
especially Products
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Dupatox® Tablets - Dydrogesterone 10 mg Tablets

     
  HOME >> PRODUCTS >> Taj Products >> Dupatox
 Taj  ALL Products View Products According to Category

Dupatox - Dydrogesterone 10 mg Tablets

(Dupatox Leaflet)      

Dupatox® Tablets
Dydrogesterone 10 mg Tablets

Active Ingredients:
1 tablet contains dydrogesterone (9beta,10alpha-pregna-4,6-diene-3,20-dione) 10 mg.

COMPOSITION
1 tablet contains dydrogesterone 10 mg.

PHARMACOLOGICAL CLASSIFICATION
A. 21.8.2 Progesterones without estrogens

Dydrogesterone 10 mg Tablets dydrogesterone (9beta,10alpha-pregna-4,6-diene-3,20-dione) 10 mg
 

Dupatox Dydrogesterone 10 mg Tablets

PHARMACOLOGICAL ACTION
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.
At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum.
Furthermore, Dupatox Dydrogesterone 10 mg Tablets is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol.

INDICATIONS
Irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency.
Combined with an estrogenic substance, Dupatox Dydrogesterone 10 mg Tablets can be applied in secondary amenorrhoea, dysfunctional uterine bleeding and post-menopausal complaints where endogenous progesterone deficiency is implicated.

Dupatox Dydrogesterone Manufacturer

Dupatox Dydrogesterone Tablets

CONTRA INDICATIONS
Dupatox Dydrogesterone 10 mg Tablets should not be given to patients with undiagnosed vaginal bleeding nor to those with a history of thromboembolic disorders.

DOSAGE AND DIRECTIONS FOR USE
In general
The dosage schemes below are meant as general recommendations. For optimal therapeutic effect, the dosages are to be adapted to the nature and severity of the disorder.
In irregular cycles due to endogenous progesterone deficiency
Dupatox Dydrogesterone 5 to 10 mg is recommended especially in irregular cycles due to shortened luteal phase (ie pre-menopause). Treatment should be repeated for several cycles.
In secondary amenorrhoea
Administration of Dupatox Dydrogesterone in combination with an estrogen is usually recommended as in these conditions endogenous progesterone deficiency is nearly always accompanied by estrogen deficiency. 0,05 mg ethinylestradiol is administered each day from the 1st to the 25th day of the cycle, and 5 mg Dupatox Dydrogesterone is added twice daily from the 11th to the 25th day. Five days after the subsequent withdrawal bleeding, the same is repeated to imitate a natural cycle.
In dysfunctional uterine bleeding
The symptomatic treatment is aimed at stopping the bleeding and including a subsequent withdrawal bleeding.

 

To stop bleeding:
Dupatox Dydrogesterone 10 mg together with 0,10 mg ethinylestradiol twice daily for 5 to 7 days.

-

To prevent heavy bleedings:
Dupatox Dydrogesterone 5 mg twice daily from day 11 to day 25 of the cycle, if necessary, combined with an estrogen during the first half of the cycle.

In post-menopausal complaints
If for the symptomatic treatment of post-menopausal complaints estrogens are used (hormone replacement therapy - HRT), Dupatox Dydrogesterone 10 mg is used to counteract the effects of unopposed estrogens on the endometrium. A subsequent withdrawal bleeding is induced.

-

If on continuous estrogen therapy:
Dupatox Dydrogesterone 10 mg twice daily during the first 12 to 14 days of each calendar month.

-

If on cyclic estrogen therapy:
Dupatox Dydrogesterone 10 mg twice daily during the last 12 to 14 days of the treatment.

Dupatox Dydrogesterone Taj Pharma Ltd.

SIDE EFFECTS AND SPECIAL PRECAUTIONS
Side effects of Dupatox Dydrogesterone may include gastro-intestinal disturbances, allergic skin rashes or urticaria, changes in libido, acne, fluid retention, mass gain, mental depression and breast changes, which may include discomfort or gynaecomastia. Alterations in liver function tests have been reported and less frequently jaundice.
In a small percentage of the treated cases, breakthrough bleeding may occur, which can be prevented by increasing the dosage. During the clinical application of Dupatox Dydrogesterone, no virilising side effects were observed.
Dupatox Dydrogesterone should be used with caution in patients with cardiovascular, renal or hepatic impairment, diabetes mellitus, asthma, epilepsy and migraine. It should be used with care in persons with a history of mental depression.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
See "Side effects and special precautions". Treatment is symptomatic and supportive.

IDENTIFICATION
Round, flat, white tablets with bevelled edges, one side with an inscription “S”, the other side with “155”on either side of the break mark.

PRESENTATION
Available in packs of 30 tablets.

STORAGE INSTRUCTIONS
Store in a dry, dark place at temperatures not exceeding 25°C. Keep out of reach of children.

Dydrogesterone is an orally active progestogen

Dydrogesterone 10 mg Tablets - Dydrogesterone 10 mg Tablets


        For more information, please see Full Prescribing Information.

 


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)
 

 

Dydrogesterone 10 mg Tablets

 

 

              
 Print page   Send by mail

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

Dupatox®; contains Dydrogesterone 10 mg Tablets Dupatox side effects Dupatox use Dupatox overdose Dupatox drug Dupatox composition dydrogesterone Manufacturing Pharmaceutical Dupatox® brand contains dydrogesterone Dupatox side effects Dupatox use Dupatox overdose Dupatox drug Dupatox composition dydrogesterone tablets Manufacturing Pharmaceutical manufacturers Dupatox® contains dydrogesterone Manufacturing dydrogesterone Pharmaceutical manufacturers Dupatox side effects Dupatox use Dupatox - dydrogesterone overdose Dupatox drug Dupatox composition dydrogesterone tablets Pharmaceuticals Allopathic Products Manufacturer exporter Supplier india formulations medicines injections insulin Pharmaceutical Product Manufacturing pharmaceuticals custom manufacturing pharmapharmacy Dupatox pharmaceutical drugs pharmaceutical formulations active pharmaceutical ingredients manufacturer pharmaceutical packaging pharmaceutical drugs global pharmaceutical pharmaceutical industry pharmaceutical raw materials pharmaceutical drug manufacturers

 
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM



















 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

www.tajpharma.com
 

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement